Highest-materiality recent filing
USPH Q1 revenue $198.3M (+7.9% YoY); GAAP loss $0.12/share, adjusted EBITDA rises to $20.2M
Revenue $198.3M, up 7.9% YoY; GAAP net income $5.0M, loss per share $0.12 vs EPS $0.80 prior year.
USPH enters $450M credit facility with $275M revolver and $175M term loan, maturing 2031
New $450M credit facility comprises $275M revolver and $175M term loan, matures April 14, 2031.
USPH reports FY2025 Adj. EBITDA $95M (+16%); CFO resigns; dividend raised to $0.46
FY2025 net revenue $781M (+16.3% YoY); Adj. EBITDA $95M (+16.2%); GAAP EPS $1.42 vs $1.84 prior.
Acquired 70% of industrial injury prevention business for ~$15.1M; target generates ~$7M in annual revenue.
US Physical Therapy Q3 revenue up 17.8% to $168.1M; EPS $0.48; reaffirms FY2025 guidance
Revenue $168.1M (+17.8% YoY); USPH Net Income $13.1M ($0.48 EPS) vs $6.6M ($0.39 EPS) prior year.
US Physical Therapy Q2 net income $12.4M; raises FY Adj EBITDA guidance to $93M-$97M
Q2 total revenue from PT ops $168.3M (+17.3%), IIP revenue $29.1M (+22.6%); record patient visits 1.56M (+16.7%).
USPH Q1 net income $9.9M ($0.80 EPS); revenue up 16.4% to $183.8M
Net income $9.9M ($0.80 EPS) vs $8.0M ($0.46) in Q1 2024.
USPH Q4 revenue up 14.2% to $180.4M; adjusted EBITDA $21.8M; dividend raised to $0.45
Q4 net revenue $180.4M (PT $153.8M + IIP $26.6M), vs $154.8M prior year; full-year revenue $671.3M.
USPH Q3: Adjusted EPS $0.55, record visits, IIP revenue up 30%, two acquisitions
Q3 GAAP EPS $0.39 (net income $6.6M); adjusted EPS $0.55 excluding $2.5M (net) clinic closure costs.
USPH closes $76.5M acquisition of 50% interest in Metro, 50-clinic operator
Paid ~$76.5M: $75M cash plus 18,358 shares of USPH common stock.
U.S. Physical Therapy acquires 50% stake in 50-clinic MSO for $76.5M
Purchase price $76.5M ($75M cash + $1.5M in USPH stock); sellers can earn up to $20M additional earnout based on performance.
USPH Q2 revenue up 8.5% to $143.5M; EPS $0.47 vs $0.64; guidance reaffirmed at $80-85M EBITDA
GAAP net income $7.5M ($0.47 diluted EPS) vs $10.9M ($0.64) in Q2 2023; share count up from May 2023 secondary offering.
US Physical Therapy Q1 revenue up 4.1%, EPS $0.46; raises FY 2024 EBITDA guidance to $82.5M-$87.5M
Q1 2024 net income $8.0M ($0.46 EPS) vs $7.4M ($0.58 EPS) in prior year; adjusted EBITDA $16.7M.
In connection with the transactions contemplated by the Purchase Agreement, and effective as of February 24, 2025, the Company expanded its board of directors (the “Board”) from seven to eight directors and appointed Michael G. Mayrsohn as a director of the Company to fill such vacancy.
Mr. Reading replaces Edward L. Kuntz, who retired as the Chairman of the Company’s Board of Directors as of the Annual Meeting.
the Board of Directors of the Company appointed Mr. Christopher J. Reading, the Company’s Chief Executive Officer since 2004 and a member of the Board of Directors, to also serve as Chairman of the Board of Directors.
In addition, Dr. Bernard Harris will now serve as the Lead Independent Director on the Board of Directors.
The Company has also promoted Eric Williams to the office of President effective as of the completion of the Annual Meeting.
on May 16, 2023, Ms. Nancy Ham was elected to serve on board of directors (the “Board”) of U.S. Physical Therapy, Inc. (the “Company”) (NYSE: USPH)
Effective April 28, 2022, Jake J. Martinez, age 43, joined U. S. Physical Therapy, Inc. as Senior Vice President/Finance and Accounting.
On March 17, 2022, Rick Binstein, was appointed as an Executive Vice President of the Company.
U.S. Physical Therapy, Inc. ("USPH" or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that its Board of Directors, upon recommendation of its Nominating Committee, has appointed Anne Motsenbocker, age 60, to serve on the Board, effective January 1, 2022.
Mr. McDowell will retire from his position as Chief Operating Officer – West effective August 31, 2021.
Max materiality 0.80 · Median 0.35 · Most common event other_material